 |
 Play Video: The Importance of Insider Buying
|
|
|
| Date | Insider | Price | Amount |
|---|
12-7-2023
Insider Buy |
Paul Y. Song
Chief Executive Officer |
$3.30
CAGR »
|
$500.23
151 shares |
12-4-2023
Insider Buy |
James A. Graf
Interim CFO |
$3.24
CAGR »
|
$2,172.50
670 shares |
12-5-2023
Insider Buy |
Paul Y. Song
Chief Executive Officer |
$3.17
CAGR »
|
$849.95
268 shares |
11-27-2023
Insider Buy |
Paul Y. Song
Chief Executive Officer |
$2.88
CAGR »
|
$700.60
244 shares |
11-22-2023
Insider Buy |
Paul Y. Song
Chief Executive Officer |
$2.82
CAGR »
|
$430.00
153 shares |
11-21-2023
Insider Buy |
James A. Graf
Interim CFO |
$2.93
CAGR »
|
$67.30
23 shares |
Also See: Institutional Holders of NKGN
Also See: SEC filings
Below we present the annualized performance delivered by Nkgen Biotech stock since 12-7-2023 (the date of the most recent
insider purchase). The performance of the investment from the time Nkgen Biotech insider buying occurred is the ultimate
test of whether insiders were right about NKGN being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
12/08/2023 |
|
| End date: |
05/01/2024 |
|
| Start price/share: |
$3.40 |
|
| End price/share: |
$1.46 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-57.06% |
|
| Annualized Gain: |
-144.63% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$4,294.00 |
|
| Years: |
0.39 |
|
Nkgen Biotech Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Nkgen Biotech insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding NKGN
|
|
Free NKGN Email Alerts:
